Sign in Subscribe
Pharmaceutical industry

Endocrinology Drugs Market to Grow by USD 36.55 Billion from 2022 to 2027, Driven by Increase in Incidence of Endocrine Disorders

Strategic Insights

— 2 min read

The endocrinology drugs market is expected to experience significant growth over the next five years, driven by the increasing prevalence of endocrine disorders such as diabetes. The market is segmented by distribution channel, therapy area, and geography, with North America contributing 45% to the growth of the global market. The rapid growth momentum in the North American market is attributed to the aging population and the high prevalence of diabetes.

Key Takeaways:

  • The endocrinology drugs market is expected to grow by USD 36.55 billion from 2022 to 2027, at a CAGR of 7.82% during the forecast period.
  • The market is segmented by distribution channel (Hospital pharmacies, Retail pharmacies, and Online pharmacies), therapy area (diabetes drugs, HGH, thyroid hormone, others), and geography (North America, Europe, Asia, and Rest of World (ROW)).
  • The most common non-communicable disease in the world is diabetes, with three major types: type-1 diabetes, type-2 diabetes, and gestational diabetes.
  • The average prevalence rate of diabetes among the global population is 9.2%, making it a major public health problem.
  • The increasing prevalence of endocrine disorders can be attributed to the increasing aging of the world population, with the elderly population at high risk of these diseases.
  • The high prevalence of diabetes is the main revenue driver for the regional market, with the increasing incidence of diabetes worldwide driving growth in the diabetic drugs segment.
  • Patient education initiatives by organizations such as the American Diabetes Association and the American Association of Diabetes Educators are also driving market growth in the region.
  • The CDC and the National Institute of Diabetes, Digestive, and Kidney Diseases are conducting training programs for healthcare professionals, which are expected to drive market growth during the forecast period.
  • The market share growth by the diabetes drugs segment will be significant during the forecast period, with the diabetic drugs segment expected to experience an increase in growth.
  • The market size is estimated to grow at a CAGR of 6.05% between 2022 and 2027 in the global migraine drugs market.
  • The market size is estimated to grow at a CAGR of 12.5% between 2022 and 2027 in the anti-obesity drugs market.

Statistics:

  • The endocrinology drugs market size is expected to grow by USD 36.55 billion from 2022 to 2027.
  • The CAGR of the market during the forecast period is expected to be 7.82%.
  • The market size is estimated to grow at a CAGR of 6.05% between 2022 and 2027 in the global migraine drugs market.
  • The market size is estimated to grow at a CAGR of 12.5% between 2022 and 2027 in the anti-obesity drugs market.

Sources:

  • Technavio Research
  • American Diabetes Association
  • American Association of Diabetes Educators
  • CDC (Centers for Disease Control and Prevention)
  • National Institute of Diabetes, Digestive, and Kidney Diseases

Read more